The company is set to reveal on Monday data from a mid-stage trial of its new drug, which handles a rare form of pain called trigeminal neuralgia, the report said.
Convergence Chief Executive
Most Popular Stories
- Americans Still Pessimistic Despite Economic Growth
- Bogdanovitch Delivers Laughs With 'She's Funny'
- Labor Day Travel Up, Gas Prices Down
- Nintendo Launching 'Amiibo' Toy-game Franchise
- U.K. Raises Terror Threat Level to 'Severe'
- Apple to Unveil New Items on Sept. 9
- Parra Joins Exclusive Club of Hispanic CEOs
- Axxis Solutions Appoints Benites as CEO
- Obama Puts Ukraine Violence on Russia
- Canada, Russia Go to War (on Twitter)